JETSTENT trial results: impact on ST-segment elevation myocardial infarction interventions

Area of Science:

• Cardiology
• Interventional Cardiology
• Biomedical Engineering

Background:

• Meta-analyses on manual thrombus aspiration and mechanical thrombectomy for acute myocardial infarction (AMI) have yielded conflicting conclusions.
• The interpretation of existing meta-analyses is significantly influenced by two large, pivotal trials: TAPAS for manual aspiration and AIMI for mechanical thrombectomy.
• The clinical impact of rheolytic thrombectomy in AMI remains a subject of debate due to divergent trial outcomes.

Purpose of the Study:

• To critically evaluate the existing evidence on manual thrombus aspiration versus mechanical thrombectomy in the context of primary percutaneous coronary intervention (PCI) for AMI.
• To analyze the influence of key trials, TAPAS and AIMI, on the overall conclusions of meta-analyses.
• To incorporate recent trial data, such as JETSTENT, to reassess the efficacy and safety of mechanical thrombectomy in AMI.

Main Methods:

• Review and synthesis of meta-analysis findings comparing manual thrombus aspiration and mechanical thrombectomy.
• Analysis of individual patient data and outcomes from landmark trials including TAPAS, AIMI, and JETSTENT.
• Evaluation of rheolytic thrombectomy's impact on survival and clinical benefit in primary PCI for AMI.

Main Results:

• Meta-analyses initially favored manual aspiration catheters and cautioned against mechanical thrombectomy devices.
• The TAPAS trial demonstrated a clinical benefit for manual aspiration in thrombus removal during PCI.
• The AIMI trial indicated a negative impact of rheolytic thrombectomy on survival, while the more recent JETSTENT trial showed a strong clinical benefit for rheolytic thrombectomy in primary PCI for AMI.

Conclusions:

• The efficacy of manual thrombus aspiration in AMI is supported by evidence.
• Mechanical thrombectomy, specifically rheolytic thrombectomy, shows promising clinical benefits in recent trials like JETSTENT for AMI, challenging earlier negative findings from the AIMI trial.
• Further research and careful consideration of trial methodologies are crucial for definitive conclusions on mechanical thrombectomy devices in AMI treatment.